FTC’s Challenge to Amgen-Horizon Merger Sparks Industry Attention

Amgen’s acquisition of Horizon Therapeutics, announced as the largest biopharma buyout in 2022, is facing delays in its closure timeline. Initially targeting the first half of 2023, the companies now aim to complete the deal by mid-December due to a lawsuit brought by the Federal Trade Commission (FTC) in May.